鹰瞳科技（Airdoc）成立于2015年，致力于“让健康无处不在 ”，为人们提供慢性病早筛及管理、近视防控、斜弱视治疗等全方位的人工智能解决方案，是全球视网膜影像人工智能领域的领导者，也是国内第一家荣获NMPA眼科人工智能三类辅助诊断医疗器械注册的企业。

    2021年11月，鹰瞳科技于香港联交所成功上市，成为“医疗AI第一股”。

    目前公司相关人工智能视网膜影像产品已为数千万用户提供疾病辅助诊断及健康风险评估。

Airdoc Technology (Airdoc) was founded in 2015, dedicated to "making health  ubiquitous," providing people with comprehensive artificial intelligence solutions  for early screening and management of chronic diseases, myopia prevention and  control, and strabismus and amblyopia treatment. It is a global leader in the field  of retinal imaging artificial intelligence and the first domestic company to receive  NMPA registration for ophthalmic artificial intelligence Class III auxiliary diagnostic  medical devices.In November 2021, Airdoc Technology was successfully listed on  the Hong Kong Stock Exchange, becoming the first "medical AI stock." Currently,  the company's relevant AI retinal imaging products have provided disease auxiliary  diagnosis and health risk assessment for tens of millions of users.

地址：北京市海淀区西三环北路甲2号院2号楼4层21室

Room 21, 4th Floor, Building 2, Yard 2, North Road of West

Third Ring, Haidian District, Beijing